Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / ANXA3

ANXA3

Basics

Aliases:
This biomarker is also known as:
  • Placental anticoagulant protein III,
  • Annexin III (lipocortin III),
  • PAP-III,
  • placental anticoagulant protein III,
  • inositol 1,2-cyclic phosphate 2-phosphohydrolase,
  • 35-alpha calcimedin,
  • calcimedin 35-alpha,
  • Annexin III,
  • Lipocortin III,
  • annexin-3,
  • annexin A3,
  • Annexin-3,
  • lipocortin III,
  • annexin III (lipocortin III, 1,2-cyclic-inositol-phosphate phosphodiesterase, placental anticoagulant protein III, calcimedin 35-alpha),
  • Inositol 1,2-cyclic phosphate 2-phosphohydrolase,
  • ANX3,

View in BioMuta

Description…

annexin A3

Attributes

QA State: Under Review
Type: Gene
Short Name:
HGNC Name: ANXA3

Datasets

There are no datasets associated with this biomarker.

Organs

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

Publications

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

Resources

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

2016 EDRN PI Orientation

The New and Continuing EDRN Principal Investigator Orientation will take on a date and location to be determined.